Company Overview and News

 
Damages Awarded in Lawsuit Against Exis, Adam Sender and Andrew Heller

2018-10-16 globenewswire
TORONTO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH and FFH.U) announces that a jury verdict in its lawsuit filed in 2006 seeking damages for alleged stock market manipulation involving Fairfax shares has awarded Fairfax and its Crum & Forster subsidiary damages of US$10.9 million against Exis Capital Management and related Exis companies, Adam Sender and Andrew Heller, including punitive damages of US$3.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Intention to Make a Normal Course Issuer Bid for Subordinate Voting Shares and Preferred Shares

2018-09-25 globenewswire
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH)(TSX: FFH.U) announces that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Fairfax of its intention to commence a Normal Course Issuer Bid (“NCIB”) through the facilities of the TSX (or other alternative Canadian trading systems) for its Subordinate Voting Shares and the following series of its Preferred Shares: Cumulative 5-Year Rate Reset Preferred Shares, Series C (“Series C Shares”), Cumulative Floating Rate Preferred Shares, Series D (“Series D Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series E (“Series E Shares”), Cumulative Floating Rate Preferred Shares, Series F (“Series F Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series G (“Series G Shares”), Cumulative Floating Rate Preferred Shares, Series H (“Series H Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series I (“Series I Shares”), Cumulative Floating Rate Preferred Shares, Series J (“Series J Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series K (“Series K Shares”) and Cumulative 5-Year Rate Reset Preferred Shares, Series M (“Series M Shares” and, together with the Series C Shares, Series D Shares, Series E Shares, Series F Shares, Series G Shares, Series H Shares, Series I Shares, Series J Shares and Series K Shares, the “Preferred Shares”).
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Fairfax Settles Lawsuit With Morgan Keegan

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH and FFH.U) announces that it has agreed, in exchange for the receipt of a payment of US$20 million, to resolve its claims against Morgan Keegan & Company, Incorporated made in its lawsuit filed in 2006 seeking damages for alleged stock market manipulation involving Fairfax shares. Fairfax continues to pursue its remaining claims against other defendants in that lawsuit, including by way of appeals against court decisions adverse to Fairfax.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Fairfax Announces Quarterly Dividend on Series C, D, E, F, G, H, I, J, K and M Preferred Shares and Quarterly Dividend Rate for Series D, F, H and J Shares

2018-08-31 globenewswire
TORONTO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has declared the following quarterly dividends per share on its preferred shares:
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Fairfax Donating US$1 Million for Kerala Flood Relief

2018-08-28 globenewswire
TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH and FFH.U), recognizing the shattering scope of the recent floods in Kerala, India, is donating US$1 million towards relief and recovery from those floods, working primarily through the Red Cross.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Second Quarter Financial Results

2018-08-02 globenewswire
(Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are prepared using the recognition and measurement requirements of International Financial Reporting Standards except as otherwise noted, and are unaudited.)
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Fairfax Announces Conference Call

2018-07-19 globenewswire
TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX:FFH) (TSX:FFH.U) will hold a conference call at 8:30 a.m. Eastern Time on Friday, August 3, 2018 to discuss its 2018 second quarter results which will be announced after the close of markets on Thursday, August 2 and will be available at that time on its website www.fairfax.ca. The call, consisting of a presentation by the company followed by a question period, may be accessed at (800) 857-9641 (Canada and U.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

10
Fairfax Announces Quarterly Dividend on Series C, D, E, F, G, H, I, J, K and M Preferred Shares and Quarterly Dividend Rate for Series D, F, H and J Shares

2018-06-01 globenewswire - 1
TORONTO, June 01, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that it has declared the following quarterly dividends per share on its preferred shares:
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Completes €150 Million Re-opening of 2.75% Senior Notes Due 2028

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) has completed its previously announced offering of an additional €150 million of its 2.75% Senior Notes due 2028 (the “Notes”). Together with the previously issued €600 million aggregate principal amount of notes of this series (the “Original Notes”), there is €750 million aggregate principal amount of notes of this series outstanding.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
First Quarter Financial Results

2018-05-03 globenewswire
(Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are prepared using the recognition and measurement requirements of International Financial Reporting Standards except as otherwise noted, and are unaudited.)
FXFLF 500413 FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF THOMASCOOK

9
Result of Voting for Directors at Annual and Special Shareholders’ Meeting

2018-04-27 globenewswire
TORONTO, April 27, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) is pleased to announce the results of the vote on Directors at its April 26, 2018 Annual and Special Shareholders’ Meeting.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
First Quarter Accounting Gain

2018-04-24 globenewswire
TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that its 67.6% - owned subsidiary, Thomas Cook (India) Limited (“TCIL”), has changed the accounting for its ownership interest in Quess Corp. Limited (“Quess”) from a subsidiary to an associate for its year ended March 31, 2018. As a result of this accounting change, TCIL will de-consolidate Quess and TCIL’s remaining ownership interest in Quess will be recorded at fair value and presented as an investment in an associate company.
FXFLF 500413 FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF THOMASCOOK

9
Fairfax Announces Conference Call

2018-04-19 globenewswire
TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX:FFH) (TSX:FFH.U) will hold a conference call at 8:30 a.m. Eastern Time on Friday, May 4, 2018 to discuss its 2018 first quarter results which will be announced after the close of markets on Thursday, May 3 and will be available at that time on its website www.fairfax.ca. The call, consisting of a presentation by the company followed by a question period, may be accessed at (800) 857-9641 (Canada and U.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Completes US$600 Million Senior Notes Offering

2018-04-17 globenewswire
TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) has completed its previously announced offering of US$600 million in aggregate principal amount of 4.850% Senior Notes due 2028 (the “Notes”). In anticipation of the offering of the Notes, Fairfax initiated a hedge of the treasury benchmark related to the Notes. After giving effect to the benefit of this hedge, the effective interest rate on the Notes is 4.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

9
Fairfax Announces Pricing of Senior Notes Offering

2018-04-13 globenewswire
TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH) (TSX:FFH.U) announces that it has priced its previously announced private offering of US$600,000,000 of Fairfax’s Senior Notes due 2028 (the “Notes”) at an issue price of 99.765%. The Notes will be unsecured obligations of Fairfax and will pay a fixed rate of interest of 4.850% per annum. In anticipation of the offering of the Notes, Fairfax initiated a hedge of the treasury benchmark related to the Notes.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:FFH / Fairfax Financial Holdin on message board site Silicon Investor.

Fairfax Financial (FFH.to) Fairfax Financial (FFH.to) Fairfax Financial (FFH.to)